BACKGROUND: South Africa has a large burden of extensively drug-resistant tuberculosis
(XDR-TB); only 15% of XDR-TB patients have successful outcomes. OBJECTIVE: To …

Tuberculosis (TB) is the ninth cause of global death, more than any other infectious disease.
With growing drug resistance the epidemic remains and will require significant attention and …

Existing therapies for multi-drug resistant tuberculosis (MDR-TB) have substantial
limitations, in terms of their effectiveness, side-effect profile, and complexity of …

Introduction: Outcomes of treatment for resistant tuberculosis are poor, with long treatment
duration and poor tolerability. Bedaquiline is a novel anti-mycobacterial drug, which has a …

Background At a time when programs were struggling to design effective regimens for the
treatment of multidrug-resistant tuberculosis (MDR-TB), the marketing authorization of …

Background Patients with highly drug-resistant forms of tuberculosis have limited treatment
options and historically have had poor outcomes. Methods In an open-label, single-group …

Tuberculosis is an airborne infectious disease treated with combination therapeutic
regimens. Adherence to long-term antituberculosis therapy is crucial for maintaining …

The new drugs delamanid and bedaquiline are increasingly being used to treat multidrug-
resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB). The World Health …

Background New anti-tuberculosis regimens that are shorter, simpler, and less toxic than
those that are currently available are needed as part of the global effort to address the …

Corbett expects that bedaquiline will soon find its way into TB regimens for HIV-positive
patients with MDR-TB. The simultaneous treatment of HIV and TB, however, raises the …